Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

PURPOSE: PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III trial in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4). PATIENTS AND METHODS:...

Full description

Bibliographic Details
Main Authors: Hecht, JR, Trarbach, T, Hainsworth, J, Major, P, Jäger, E, Wolff, R, Lloyd-Salvant, K, Bodoky, G, Pendergrass, K, Berg, W, Chen, B, Jalava, T, Meinhardt, G, Laurent, D, Lebwohl, D, Kerr, D
Format: Journal article
Language:English
Published: 2011

Similar Items